Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal Study

  • Enveric Biosciences ENVB announced data from a preclinical rodent model evaluating EV102, the company's cannabidiol (CBD) based product in development for the topical treatment of radiodermatitis.
  • Radiodermatitis, the most common side effect of radiation therapy, is a physical skin irritation with symptoms ranging from red rash to open wounds. It affects nearly 95% of patients who receive radiation for cancer treatment.
  • EV102 was topically applied during a daily treatment regimen and resulted in a nearly 50% reduction in redness scoring severity. 
  • Similar results were obtained for overall dermatitis severity, including desquamation (skin peeling) and ulceration as part of a composite score. 
  • The company plans to start Phase 1 study in 2H of 2022.
  • Related Link: You Ask, We Analyze: Enveric Biosciences Stock Looks Ready To Skyrocket.
  • Price Action: ENVB shares are down 2.61% at $1.66 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCancer TreatmentRadiation Therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!